# US 2019/0315729 A1 · Fxr (nr1h4) modulating compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315729 A1
- Document ID: US20190315729A1
- Status: Published application
- Kind: A1
- Application number: 16/409,184
- Filed: 2019-05-10
- Published: 2019-10-17
- Earliest claimed: 2016-06-13
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Peter A. Blomgren; Kevin S. Currie; Julie Farand; Christian Gege; Jeffrey E. Kropf; Jianjun Xu
- Web page: https://patentgrep.com/patent/US20190315729A1

## CPC

- C07D 413/14: containing three or more hetero rings
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/38: of the suprarenal hormones
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

## Claims

### Claim 1

A compound according to Formula (I):
wherein:
i) Q is phenylene or pyridylene, each of which is optionally substituted with one or two substituents selected from halogen, methyl, —CH2F, —CHF2, or —CF3;
Z is:
and
X is CH, C—CH3, or N; or
ii) Q is pyridylene optionally substituted with one or two substituents selected from halogen, methyl, —CH2F, —CHF2, or —CF3;
Z is:
and
X is CH, C—CH3, or N; or
iii) Q is phenylene optionally substituted with one or two substituents selected from halogen, methyl, —CH2F, —CHF2, or —CF3;
Z is:
and
X is N;
L is selected from the group consisting of a bond, C1-3-alkylene, and C1-3-alkylene-O—;
R1 is C1-4-alkyl or C3-6-cycloalkyl, wherein:
said C1-4-alkyl is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxyl, C1-3-alkoxy, and fluoro-C1-3-alkoxy; and
said C3-6-cycloalkyl is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxyl, C1-3-alkyl, fluoro-C1-3-alkyl, C1-3-alkoxy, and fluoro-C1-3-alkoxy;
R2 is hydrogen, fluoro, CH3, —CH2F, —CHF2, or CF3;
R3 is halogen, C1-4-alkyl, halo-C1-4-alkyl, C1-4-alkoxy, or halo-C1-4-alkoxy;
R4 is hydroxyl, C1-6-alkoxy, halo-C1-6-alkoxy, or —NR5R6;
R5 is hydrogen, C1-6-alkyl, or halo-C1-6-alkyl;
R6 is hydrogen or C1-6-alkyl, wherein said C1-6-alkyl is optionally substituted with 1 to 6 substituents independently selected from halogen, —SO3H, and —CO2H;
R7 and R8 are independently selected from halogen, C1-3-alkoxy, and fluoro-C1-3-alkoxy; and
n is 0 or 1;
or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R4 is hydroxyl; or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein Q is phenylene substituted with one chloro; or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein:
L is a bond;
R1 is C1-4-alkyl or C3-6-cycloalkyl;
R2 is hydrogen; and
R7 and R8 are independently selected from halogen, C1-3-alkoxy, and fluoro-C1-3-alkoxy;
or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R1 is cyclopropyl; or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

### Claim 6 (depends on 1)

The compound of claim 1, wherein
is:
or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

### Claim 7

A compound of formula:
or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

### Claim 9 (depends on 1)

A method of treating a patient having a disease or condition mediated, at least in part by FXR, comprising administering a compound of claim 1 to the patient in need thereof.

### Claim 10 (depends on 9)

The method according to claim 9 wherein the FXR mediated condition is selected from the group consisting of:
a chronic intrahepatic or some form of extrahepatic cholestatic condition;
liver fibrosis;
an obstructive inflammatory disorder of the liver;
chronic inflammatory disorder of the liver;
liver cirrhosis;
liver steatosis or an associated syndrome;
cholestatic or fibrotic effects that are associated with alcohol-induced cirrhosis or with viral-borne forms of hepatitis;
liver failure or liver ischemia after major liver resection;
chemotherapy associated steatohepatitis (CASH);
acute liver failure; and
Inflammatory Bowel Disease.

### Claim 11 (depends on 9)

The method according to claim 9 wherein the FXR mediated condition is selected from the group consisting of:
a lipid and lipoprotein disorder;
Type I Diabetes;
Type II Diabetes;
clinical complications of Type I and Type II Diabetes selected from the group consisting of diabetic nephropathy, diabetic neuropathy, diabetic retinopathy and other observed effects of clinically manifest long term Diabetes;
Non-Alcoholic Fatty Liver Disease (NAFLD);
Non-Alcoholic Steatohepatitis (NASH);
obesity;
a metabolic syndrome selected from the group consisting of combined conditions of dyslipidemia, diabetes and abnormally high body-mass index;
acute myocardial infarction;
acute stroke; and
thrombosis which occurs as an endpoint of chronic obstructive atherosclerosis.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the FXR mediated condition is selected from the group consisting of
a non-malignant hyperproliferative disorder;
a malignant hyperproliferative disorder selected from the group consisting of hepatocellular carcinoma, colon adenoma, and polyposis;
colon adenocarcinoma;
breast cancer;
pancreas adenocarcinoma;
Barrett's esophagus; and
other forms of neoplastic diseases of the gastrointestinal tract and the liver.

### Claim 13

A compound of formula:
or a pharmaceutically acceptable salt thereof.
